Table 3.

No major safety signals with Toca 511 & Toca FC in Phase 3 trial.

Most Common (≥5%) Treatment Emergent Adverse Events (TEAE)				Most Common (≥2%) Treatment Emergent Serious Adverse Events (TESAE)
Grade 3-4 TEAE	Toca 511 & Toca FC (n=201)	SOC (n=199)		Grade 3-4 TESAE	Toca 511 & Toca FC (n=201)	SOC (n =199)
Aphasia	16 (8.0%)	7 (3.5%)		Brain Edema	8 (4%)	2 (1%)
Hemiparesis	15 (7.5%)	5 (2.5%)		Pulmonary Embolism	7 (3.5%)	5 (2.5%)
Headache	13 (6.5%)	10 (5%)		Seizure	7 (3.5%)	8 (4%)
Seizure	8 (4.0%)	11 (5.5%)		Hemiparesis	6 (3%)	1 (0.5%)
WBC decrease	0	10 (5.0%)		Headache	5 (2.5%)	0
TEAEs leading to treatment discontinuation	2 (1%)	5 (2.5%)		Vasogenic Cerebral Edema	4 (2.0%)	0
TEAEs Leading to death	6 (3%)	3 (1.5%)		Fall	4 (2.0%)	1 (0.5%)
No Treatment Related AEs Resulted in death				Subdural Hematoma	4 (2.0%)	1 (0.5%)